Home › Fibrolamellar hepatocellular carcinoma › Maryland › Baltimore
Fibrolamellar hepatocellular carcinoma clinical trials in Baltimore, MD
3 studies for Fibrolamellar hepatocellular carcinoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
RecruitingPhase 1
- Johns Hopkins SKCCC, Baltimore
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
RecruitingPhase 1/2
- Johns Hopkins SKCCC, Baltimore
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
RecruitingPhase 1
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Pancreatic Cancer31 studies
- Colorectal Cancer31 studies
- Metastatic Cancer28 studies
- Obesity26 studies
- Bladder Cancer24 studies
- Heart Failure24 studies
- Ovarian Cancer22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.